调节高密度脂蛋白胆固醇的药物研究进展  

Research progress of drugs regulating high-density lipoprotein cholesterol

作　　者：闫丽荣[1] 李一石[1] 

机构地区：[1]北京协和医学院中国医学科学院阜外心血管病医院,卫生部心血管药物临床研究重点实验室,北京100037

出　　处：《中国新药杂志》2013年第15期1768-1773,共6页Chinese Journal of New Drugs

基　　金：国家“重大新药创制”科技重大专项(2012ZX09303008-001);国家临床重点专科建设项目

摘　　要：流行病学资料证实高密度脂蛋白胆固醇(HDL-C)水平与冠心病发病风险负相关,近年来药物调节高密度脂蛋白胆固醇水平及功能成为研究热点。临床上常用的调脂药物可升高HDL-C,但作用轻微,近年特异作用于HDL-C代谢途径及功能的新药研发取得了一定的进展。文中对调节HDL-C的药物研究进展作一综述。目前,虽然流行病学资料及临床试验使药物调节HDL-C充满了希望,但仍需期待正在进行的大规模临床研究证实其临床获益。Epidemiological studies have consistently demonstrated a negative association between high-den- sity lipoprotein cholesterol （HDL-C） levels with the risk of coronary heart disease. As a result, HDL-C is gaining increasing interest as a therapeutic target. Currently available cholesterol-lowering medications can raise HDL-C level, but mildly. The development of new drugs, which specifically improve the metabolism and functions of HDL- C, has made some progress. In this review, we discuss the recent advance in drugs regulating HDL-C. At present, raising HDL-C level holds great promise as shown by epidemiological data and clinical trials, but we await the outcomes of the large clinical outcomes trials currently under way to define the clinical role of the therapies.

关 键 词：高密度脂蛋白胆固醇 冠心病 烟酸类药物 胆固醇酯转移蛋白抑制剂 

分 类 号：R972.6[医药卫生—药品]